James Bucher
General Counsel at HARPOON THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Profile
James B.
Bucher currently works at Harpoon Therapeutics, Inc., as Chief Legal Officer from 2023.
Mr. Bucher also formerly worked at Exelixis, Inc., as Secretary & Vice President-Corporate Legal Affairs from 2013 to 2014, Shearman & Sterling LLP, as Partner from 2001 to 2007, Lundbeck Seattle BioPharmaceuticals, Inc., as Executive Vice President & General Counsel, and Eliem Therapeutics, Inc., as Executive Vice President & General Counsel.
Mr. Bucher received his undergraduate degree from Colgate University and graduate degree from Emory University School of Law.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
-.--% | 2024-03-30 | 0 ( -.--% ) | - $ | 2024-04-29 |
James Bucher active positions
Companies | Position | Start |
---|---|---|
HARPOON THERAPEUTICS, INC. | General Counsel | 2023-12-25 |
Former positions of James Bucher
Companies | Position | End |
---|---|---|
EXELIXIS, INC. | General Counsel | 2013-12-31 |
Shearman & Sterling LLP
Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Corporate Officer/Principal | 2006-12-31 |
ELIEM THERAPEUTICS, INC. | General Counsel | - |
ALDER BIOPHARMACEUTICALS, INC. | General Counsel | - |
Training of James Bucher
Emory University School of Law | Graduate Degree |
Colgate University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
EXELIXIS, INC. | Health Technology |
ELIEM THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Shearman & Sterling LLP
Shearman & Sterling LLP Miscellaneous Commercial ServicesCommercial Services Shearman & Sterling LLP provides legal services. It specializes in appellate litigations, capital markets, corporate governance, environmental, finance, international arbitration, investment funds, litigation, mergers and acquisitions, privatization, real estate, and tax. The company was founded by Thomas Shearman in 1873 and is headquartered in New York, NY. | Commercial Services |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- James Bucher